Authors: Shivank Bhatia, MD, Sardis H. Harward, MPH, Vishal K. Sinha, BS, and Govindarajan Narayanan, MD
By: Sangik Park, MD, Ji Hoon Shin, MD, Dong-Il Gwon, MD, Hyoung Jung Kim, MD, Kyu-Bo Sung, MD, Hyun-Ki Yoon, MD, Gi-Young Ko, MD, and Heung Kyu Ko, MD
Abstract: To evaluate outcomes of transcatheter arterial embolization (TAE) for gastric cancer-related gastrointestinal (GI) bleeding and factors associated with successful TAE and improved survival after TAE.
Materials and Methods: This retrospective study included 43 patients with gastric cancer related GI bleeding undergoing angiography between January 2000 and December 2015. Clinical course, laboratory findings, and TAE characteristics were reviewed. Technical sucess of TAE was defined as target area revascularization, and clinical success was defined as bleeding cessatation with hemodynamic stability during 72 hours after TAE. Student t test was used for comparison of continuous variables, and Fischer exact test was used for categorical variables. Univariate and multivariate analysis were performed to identify predictors of successful TAE and 30-day survival after TAE.
Results: TAE was performed in 40 patients. Technical and clinical success rates of TAE were 85.0% and 65.0%, respectively. Splenic infarction occured in 2 patients as a minor complication. Rebleeding after TAE occured in 7 patients. Death related to bleeding occured in 5 patients. Active bleeding and higher transfusion requirement were associated with TAE failure. Successful TAE predicted improved 30-day survival after TAE on univariate and multiraviate analysis.
Conclusion: TAE for gastric cancer-associated GI bleeding may be a lifesaving procedure. Severe bleeding with a higher transfusion requirement and active bleeding on angiography predicted TAE failure.
Purpose: To evaluate efficacy and safety of a novel device that combines an inferior vena cava (IVC) filter and central venous catheter
(CVC) for prevention of pulmonary embolism (PE) in critically ill patients.
Materials and Methods: In a multicenter, prospective, single-arm clinical trial, the device was inserted at the bedside without fluoroscopy and subsequently retrieved before transfer from the intensive care unit (ICU). The primary efficacy endpoint was freedom from clinically significant PE or fatal PE 72 hours after device removal or discharge, whichever occurred first. Secondary endpoints were incidence of acute proximal deep venous thrombosis (DVT), catheter-related thrombosis, catheter-related bloodstream infections, major bleeding events, and clinically significant thrombus (occupying > 25% of volume of filter) detected by cavography before retrieval.
Results: The device was placed in 163 critically ill patients with contraindications to anticoagulation; 151 (93%) were critically ill trauma patients, 129 (85%) had head or spine trauma, and 102 (79%) had intracranial bleeding. The primary efficacy endpoint was achieved for all 163 (100%) patients (95% confidence interval [CI], 97.8%–100%, P < .01). Diagnosis of new or worsening acute proximal DVT was time dependent with 11 (7%) occurring during the first 7 days. There were no (0%) catheter-related bloodstream infections. There were 5 (3.1%) major bleeding events. Significant thrombus in the IVC filter occurred in 14 (8.6%) patients. Prophylactic anticoagulation was not initiated for a mean of 5.5 days ± 4.3 after ICU admission.
Conclusions: This novel device prevented clinically significant and fatal PE among critically ill trauma patients with low risk of complications.
The AVIR is pleased to announce that our Annual VI Board Prep course, offered at our annual meeting each year, is now available as an online webinar.
The VI Review Course includes access to the online lecture, as well our proprietary mock registry exam. The 4 hour lecture covers all sections of the exam matrix provided by ARRT.
This course is approved for 4 CE credits.